Fundz

XOMA Royalty completes merger with Generation Bio

TAKEN PRIVATEOct 04, 2026

Acquiring Company

XOMA Royalty Corporation

Acquired Company

Generation Bio

EmeryvilleCambridgeBiotechnologyHealth CareManufacturingGeneticsTherapeutics

Description

On February 9, 2026, XOMA Royalty completed a cash merger with Generation Bio Co., paying USD 4.2913 per share. This transaction led to Generation Bio being delisted from Nasdaq, marking its transition to a wholly owned subsidiary of XOMA Royalty. The merger included a contingent value right aimed at providing potential additional payments linked to acquired assets.

Company Information

Company

XOMA Royalty Corporation

Location

Emeryville, California, United States

About

XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company has an extensive and growing portfolio of assets.

Fundz sees it the moment XOMA Royalty Corporation makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Brad
Likely contact at this company
••••••••@••••••••

See Brad's verified email →

Nicholas
Likely contact at this company
••••••••@••••••••

See Nicholas's verified email →

Brad
Likely contact at this company
••••••••@••••••••

See Brad's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for XOMA Royalty Corporation's next move

Learn about Strategic plan

Frequently asked

Who acquired Generation Bio?

Generation Bio was acquired by XOMA Royalty Corporation, based in Emeryville. The deal was reported on October 4, 2026. XOMA Royalty Corporation is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty Corporation is privately held and operates in Biotechnology.

When did XOMA Royalty Corporation acquire Generation Bio?

XOMA Royalty Corporation's acquisition of Generation Bio was reported on October 4, 2026. On February 9, 2026, XOMA Royalty completed a cash merger with Generation Bio Co., paying USD 4.2913 per share. This transaction led to Generation Bio being delisted from Nasdaq, marking its transition to a wholly owned subsidiary of XOMA Royalty. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Generation Bio do?

Generation Bio is a biotechnology company changing what is possible for people living with T cell-driven autoimmune diseases. It is privately held, operating in Manufacturing, and is based in Cambridge.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.